|
Patents
AuRx has exclusively licensed patents owned by the
University of Maryland covering the use of the recombinant virus.
This virus has been engineered to delete a gene which could possibly
lead to tumor formation thus, eliminating the transforming potential
of the virus and providing a safe vaccine.
The market for a herpesvirus therapy which is effective
in preventing outbreaks of HSV-2 is extremely large and world-wide.
This long sought after therapy is the dream of everyone currently
infected with genital herpes. In the US, it is estimated by the
CDC that the number of infected people is over 40 million. Sufferers
of genital herpes currently spend more than $2 billion each year
for drugs which only reduce the number of days in each outbreak.
In animal tests, the AuRx therapy has completely prevented the recurrence
of outbreaks in over 90% of the animals treated.
US
6,207,168 Vaccine composition for herpes simplex virus and methods
of using
US
6,054,131 Vaccine composition for herpes simplex virus and methods
of using
US
6,013,265 Vaccine composition for herpes simplex virus and methods
of using
continue
|
